Terapia con miRNAs en la enfermedad cardiovascular y envejecimiento: descubrimiento de nuevos candidatos by Pina Beltrán, Blanca et al.
  
Director: Dra. Laura Ordovás Vidal. ARAID, UNIZAR – I3A (BSICoS group) 
Directror: Dra. Estel Ramos Marquès. UNIZAR – I3A (BSICoS group)  
University Presenter: Dr Emma Sevilla Miguel – Dpto. Bioquímica y Biología Molecular y Celular  
Author: Blanca Pina Beltrán 
Trabajo de Fin de Máster en Biología Molecular y Celular 
Curso 2019-2020 
“Terapia con miRNAs en la enfermedad cardiovascular y envejecimiento: 
descubrimiento de nuevos candidatos” 
 





1. ABSTRACT ...................................................................................................................................1 
2. INTRODUCTION ..........................................................................................................................2 
3. HYPHOTHESIS AND AIMS ............................................................................................................5 
4. BIBLIOGRAPHIC REVISION ..........................................................................................................6 
4.1 microRNA: Biogenesis and function ........................................................................................6 
4.2 Basic nomenclature of the miRNA ..........................................................................................7 
4.3 micro RNAs in heart physiology and pathogenesis .................................................................7 
4.3.1 Developing heart ................................................................................................................7 
4.3.2 Cardiac remodelling after myocardial infarction: Hypertrophy, fibrosis and apoptosis ......8 
4.4 miRNAs as Biomarkers ............................................................................................................8 
4.5 Models to study cardiovascular disease and develop new therapies ................................... 10 
4.5.1 In vivo models (preclinical animal models) ....................................................................... 11 
4.5.2 In vitro and ex vivo models ............................................................................................... 12 
4.6 microRNA-based therapies ................................................................................................... 13 
4.6.1 Development of miRNA-based drugs ................................................................................ 15 
4.6.1.1 Bioinformatic analysis for target prediction ...................................................................... 15 
4.6.1.1.1 From bioinformatic prediction to the clinic ................................................................... 16 
4.6.1.2 Delivery vehicles ............................................................................................................... 17 
4.6.1.3 Administration .................................................................................................................. 19 
4.6.2 AntimiRNAs therapies ....................................................................................................... 21 
4.6.2.1 Antisense oligonucleotides ............................................................................................... 21 
4.6.2.2 BlockmiRs ......................................................................................................................... 24 
4.6.2.3 miRNA-sponges ................................................................................................................. 25 
4.6.2.4 Tough decoy (TuD) ............................................................................................................ 26 
4.6.3 miRNA mimic-based therapies .......................................................................................... 28 
4.6.4 Current state of miRNA-based drugs and repurposing to treat CV .................................... 30 
5. MATERIALS AND METHODS ...................................................................................................... 31 
5.1 Sequence Analysis and Bioinformatic tools .......................................................................... 31 
5.2 Bacteria and culture medium ............................................................................................... 31 
5.3 Cloning Vectors ..................................................................................................................... 31 
5.4 Polymerase chain reaction (PCR) .......................................................................................... 31 
5.5 Agarose gel electrophoresis .................................................................................................. 32 
5.6 Nucleic Acids purification ..................................................................................................... 32 
5.7 Cloning .................................................................................................................................. 32 
5.7.1 Vector and insert digestion ............................................................................................... 32 
 
 
5.7.2 Ligation ............................................................................................................................. 32 
5.7.3 Transformation of DH5α competent bacteria ................................................................... 33 
5.7.4 Screening of recombinant colonies ................................................................................... 33 
5.7.4.1 Colony PCR ........................................................................................................................ 33 
5.7.4.2 Enzymatic digestion .......................................................................................................... 33 
5.8 Sequencing ........................................................................................................................... 33 
5.9 Cell culture............................................................................................................................ 34 
5.10 Transfection .......................................................................................................................... 34 
5.10.1 Assessment of the transgenic miRNA expression.............................................................. 34 
6. RESULTS .................................................................................................................................... 35 
6.1 Creation of a miRNA inducible expression vector. ................................................................ 35 
6.1.1 Cloning the miRNA of interest in V5.................................................................................. 35 
6.1.1.1 miRNA amplification ......................................................................................................... 35 
6.1.1.2 Cloning of mir-4435 in the inducible expression vector .................................................... 36 
6.1.1.3 Analysis of the expression of the mir4435 inducible expression vector (V39)................... 38 
6.1.1.4 Analysis of miRNA processing to obtain mature mir4435 in Hek293 ................................ 39 
6.2 Replacement of tdT by BFP for iPSC functional characterization of the mir4435 .................. 39 
6.2.1 Cloning of BFP to replace tdT reporter gene ..................................................................... 39 
7. DISCUSSION .............................................................................................................................. 41 
8. CONCLUSIONS .......................................................................................................................... 44 
9. BIBLIOGRAPHY ......................................................................................................................... 45 








Cardiovascular diseases are, as of now, the main cause of death in the developed world. Aging is a 
main risk factor determining their development. In most of the cases, pharmacological treatments do 
not directly asses the problem and have only palliative effects, which decreases quality life of the 
patient and increase dependence on the treatment to follow a normal lifestyle. Therefore, looking for 
novel effective therapies to treat the cause of the disease will be crucial in the near future. 
microRNAs (miRNA) have been proved to be master regulators of many biological processes that take 
places in the cell, since they are capable of regulating gene expression. Studies in vitro and in vivo have 
associated dysregulation of the miRNAs expression with pathology in cardiovascular disease and aging, 
thus postulating them as possible therapeutic targets. 
As result, miRNAs-mimics and anti-miRs have emerged as a new promising therapeutic approach to 
correct gene expression alterations regulated by miRNAs that have been seen in disease. Here, a 
detailed revision of the application of miRNA-based therapies to treat CVD is made. Although, currently 
there are only 2 studies that have reached clinical trials, many preclinical studies have published 
encouraging results. 
Continuing previous work of the group BSICoS, a second aim of this master’s thesis is to develop tools 
for the study of the interaction of age-related miRNAs (BIO-AGEmiRNA) with their target genes in 
relation to cardiac function using human iPSC-derived cardiomyocytes.  A inducible expression vector 
was created to be expressed mature miRNAs, specifically miR-4435, downstream of a fluorescent 
reporter gene. The vector was tested in vitro in HEK293 cells and proper expression of the reporter 
was observed. However, expression of the mature miR-4435, and therefore proper processing of the 
pre-miRNA, could not be confirmed due to technical issues. Future work will continue to validate the 
remaining BIO-AGE-miRNAs in vitro, first in HEk393 and then in iPSC-derived cardiomyocytes were the 
molecular mechanism and functionality of the BIO-AGEmiRNAs will be investigated. The developed 






Cardiovascular diseases (CVD) are the leading cause of death worldwide accounting for 31% of total, 
almost 17.8 million deaths. Specifically, ischaemic heart disease (also called coronary heart disease, 
CHD) and stroke were the top 2 in 2016 [1]. These numbers constitute an increase of 21.1% since 2007 
[2]. Furthermore, an age-related increase in the prevalence of CVD (considering CHD, Heart Failure 
stroke, and hypertension) has been observed in both males and females in the last years (National 
Health and Nutrition Examination Survey, NHANES). Heart failure (HF) is a complex high prevalent age-
related clinical syndrome that impairs the ability of the ventricle to fill or eject blood. By 2035, it is 
predicted that approximately 45.1% of the US citizens would suffer from CVD, which would be 
associated with an enormous economic burden [2] 
By promoting healthy dietary and lifestyle habits in the population, nearly 80% of CVDs could be 
prevented, since smoking, lack of physical activity or high body mass index are the main risk factors 
[2], [3] that precipitate the development of defects in mitochondrial functionality, insulin signalling, 
endothelial homeostasis and redox balance resulting in an early appearance of senescent attributes 
leading to CVD [4]. 
Currently, pharmacological treatment is composed principally by antithrombotic agents, 
antihypertensives, diuretics, β-Blocking agents and agents acting on the renin-angiotensin system, 
which act mainly on protein targets like enzymes, receptors or transporters [5]. Surgical procedures 
are also being done and in case of severe damage, a heart transplantation could replace the failing 
organ [6]. 
The development of CVD therapeutics have increased median life‐expectancy [4]. However, CVD 
medications are associated with higher side-effects risks [7]. Together with this, patients who had 
suffered any CVD are polymedicated, which increases the likelihood of side effects due to adverse 
drug-drug interactions and complicates adherence, especially in older adults [8]. Therefore, there is 
need for highly specific medicines to ameliorate life quality and health of CVD´s patients.  
With life expectancy on the rise, the world population is becoming increasingly aged. By 2050, 16% of 
the population is expected to be over 65 and people aged over 80 to triple [9]. Aging is a physiological 
process considered a major risk factor that increases the likelihood of suffering a CVD. A number of 
age related detrimental transformations occur on the human heart like left ventricular hypertrophy, 
cardiomyocyte loss, diastolic dysfunction or cardiac fibrosis [10].  Concerning subcellular changes 
(Figure 1), mitochondrial function [11], calcium handling [11] as well as cell-cell communication 
structures (intercalated discs and gap junctions) are severely altered with age as seen in animal models 




differentiation and lifespan extension), AMPK (glucose uptake, glycolysis, oxidation of free fatty acids 
and mitochondrial biogenesis), SIRT1 (gatekeeper against oxidative stress, inflammation and 
cardiovascular aging), p66Shc (oxidative stress in mitochondria), JunD (oxidative stress) and NF‐kB 
(regulates gene expression of factors that mediate cell adhesion, proliferation, inflammation, redox 
state, and tissue‐specific enzymes) link aging with cardiovascular dysfunction [4]. Gaining knowledge 
about aging and CVD molecular basis would help researchers into development new curative 
treatments, instead of palliative ones. 
 
Figure 1. Schematic representation of the molecular mechanisms of cardiac ageing and potential 
cardiac interventions. ROS, Reactive oxygen species; CR, calorie restriction; SS, Szeto –Schiller; miRNA, 
microRNA; ACE, angiotensin-converting enzyme; Ang, angiotensin [11]. 
 
microRNAs (miRNAs) have been proved to be important master regulators of biological processes, 
including aging-related modifications in the heart [13] 
One of the research lines of the group BSICoS (Biomedical Signal Interpretation and Computational 
Simulation) is discovering miRNAs involved in human cardiac aging. Long-term aim includes 
development of possible therapies and determination of biomarkers related to heart dysfunction in 
aging. Up to now, most studies where aging was investigated considered chronological age (CA) 
instead of biological age (BA) as the main aging variable. However, CA does not always reflect the 
health status of an individual since it just accounts for time, not for environmental or genetic factors. 




CVD [14]. BSICoS analysed the human Left ventricule (LV) miRnome in relation to BA rather than just 
CA using RNAseq data form the GTEx consortium [15]. A total of 20 BA-related miRNAS (BIO-
AGEmiRNAs) (14 upregulated and 6 downregulated) were identified [15]. Then, using bioinformatic 
tools, Ramos-Marquès et al., described a heart-related BIO-AGEmiRNA gene regulation network, that 
might help to understand how LV functioning is modulated by BA-associated miRNAs at the molecular 
level. In order to validate the network, some of the putative interactions of BIO-AGEmiRNA with their 
potential target genes have been evaluated experimentally [16]. These included targets of MIR24-2 
and MIR4435-1HG and some of the miRNA-mRNA regulatory axes were in vitro validated by luciferase 
expression assays  . When miR-24-2 was assayed, 5 out of 7 target genes tested showed a positive 
interaction: ADRA1A, ACTN2, ATP2A2 (SERCA2A), POPDC2 and TMOD1. In the case of the miR-4435, 
DSP was the only one showing a significant interaction (10% reduction in the luciferase activity in 






















3. HYPHOTHESIS AND AIMS 
Since miRNAs are involved in a variety of biological processes regulating gene expression at the post-
transcriptional level, including CVD and aging, it is hypothesized that they have a therapeutic and 
biomarker potential in such processes.  
The aim of the bibliographic revision in this Master’s thesis is to summarise all the progress that has 
been done up to now in the field of miRNA therapeutics related to CVD and aging, considering both 
miRNA inhibitors and replacement therapies. Therefore, the following partial aims were proposed: 
1) Compile methods and approaches used to develop miRNA therapeutics and their most 
recent advances.  
2) Analyse the state of the art of miRNA therapeutics for CVD. 
The experimental aim of this Master’s thesis is to develop tools for the molecular and functional 
characterization of the validated interactions of BIO-AGEmiRNA with their target genes [16] in 
cardiomyocyte-derived iPSC (CM-iPSC). Future studies will use recombinase mediated cassette 
exchange (RMCE) in human induced pluripotent stem cells (hiPSC) [17] to create BIO-AGEmiRNAs 
inducible expression lines.  
In order to achieve this objective, the following partial aims are proposed: 
1) Construction of inducible expression vectors of BIO-AGEmiRNA’s for RMCE in iPSC. 
2) Analysis of the expression of the transgenic miRNA and the correct intracellular processing 













4. BIBLIOGRAPHIC REVISION 
4.1 microRNA: Biogenesis and function 
MicroRNAs (miRNAs) are small endogenous non-coding RNA constructions of 21-25 nucleotides in 
length found both in animals and plants. They display an essential posttranscriptional regulatory role 
by generally binding to the 3'untranslated region of a given target mRNA (although, binding to the 5′-
untranslated region or to the open reading frame has also been described) which results in degradation 
or in translational repression of the mRNA [13].  
Although, the majority of the miRNAs are located in non-coding intergenic regions, a few are encoded 
in intronic or exonic regions. When the latter occurs, miRNAs are usually co-transcribed with their host 
genes and processed afterwards in an independent manner. In other cases, they possess their own 
promoters and originate monocistronic transcripts. 
Yet, many miRNAs are found near each other in the 
genome creating miRNA clusters that are expressed 
polycistronically.  
miRNAs are generally transcribed by RNA polymerase 
II into a primary miRNA (pri-miRNA) that folds into its 
secondary hairpin-structure (Figure 2). The pri-miRNA 
is then cleaved in the nucleus by the Microprocessor 
(a complex formed by Drosha, a class 2 RNase III 
enzyme, and DGCR8, a dsRNA) to obtain the long 
precursor miRNA (pre-miRNA). The pre-miRNA is 
exported to the cytoplasm where a highly specific 
RNAse III cytoplasmic endonuclease (Dicer), creates a 
22-nucleotide mature miRNA duplex. Dicer will 
associate to TRBP, so that the miRNA duplex can be 
loaded onto Argonaute protein (AGO) forming the 
RISC-loading complex (RNA-induced silencing 
complex). The stability of the two ends of the duplex 
determines which strand remains bound to the AGO 
protein. Several studies suggest that an RNA Helicase 
(not identified) mediates the unwinding and removal 






loading is completed, the miRNA guides the RISC complex to its target mRNA, which is silenced through 
degradation or by blocking its translation [18] 
Contrary to siRNAs where one RNA molecule is fully complementary to one particular mRNA, 
microRNAs target complete genetic pathways which are related in function (one miRNA can target 
more than 100 genes). This is possible due to the fact that microRNAs have an approximately 7 
nucleotide match known as seed sequence that seems to be one of the primary determinants of the 
pairing specificity between the miRNA and the mRNA [19]. 
4.2 Basic nomenclature of the miRNA 
miRNA nomenclature follows basic rules [20]. Mature miRNAs have the prefix “miR” followed by an 
identifying number, e.g. miR-499. In the case of Pre-miRNAs this prefix is substituted by a lower-case 
prefix “mir” followed also by the same identifying number.   
The miRNA species can be distinguished by adding three- or four-letter prefixes before the prefix that 
indicates specie, e.g. hsa-miR-101 in Homo sapiens. An extra lower-case letter is added to differentiate 
miRNAs with similar sequences that only vary in one or two nucleotides, e.g. miR-123a or miR-123b. 
When two pre-miRNAs are located at distinct loci but lead to the same mature miRNA, an additional 
hyphen and number is added to the miRNA name, e.g. miR-194-1 or miR-194-2. 
4.3 micro RNAs in heart physiology and pathogenesis  
4.3.1 Developing heart 
The role of miRNAs in cardiac development and disease has been deeply studied. Many studies in Dicer 
knockout mice have shown that miRNAs are essential for both embryonic and postnatal cardiac 
development. Specific deletion of Dicer in embryonic mouse hearts lead to heart failure and 
subsequent death in the second half of the pregnancy [21]. Moreover, embryos in which Dicer is 
inactivated in the developing heart had a poorly developed ventricular myocardium and died soon 
after birth due to heart failure [21]. In the heart of adult mice, targeted deletion of Dicer causes early 
death and induces unfavourable cardiac remodelling [22]. 
miR-1/miR-133 family controls cell proliferation and differentiation, as well as, cardiac development 
[21]. Being specifically expressed only in cardiac and skeletal muscle, are amongst the most expressed 
miRNAs in the heart. Overexpression of miR-1 and miR-133a in developing hearts of mice diminish the 
thickness of the ventricular wall, reduces cardiomyocyte proliferation and induces heart failure leading 
to mice death [23]. The miR-17–92 cluster (miR-17, miR-18a, miR-19a, miR-19b, miR-20a and miR-92a) 




provokes immediate postnatal death due to severe ventricular failure [24]. Another example of a 
miRNA family essential during postnatal development of the heart are miR-15 family members (miR-
15a, miR-15b, miR-16, miR-195 and miR-497), which suffer an upregulation in the new-born’s 
developing heart that appears to mediate in cell survival and cell cycle regulation [25]. 
4.3.2 Cardiac remodelling after myocardial infarction: Hypertrophy, fibrosis and apoptosis  
In the adult heart, in presence of a stress situation (e.g., hypertension, heart attack), cardiac 
remodelling can be induced. This adaptative response is essential to try to maintain heart function at 
first, but when prolonged in time hypertrophic growth (massive thickening of the ventricular walls) 
becomes pathologic, and causes severe fibrosis in the myocardium, reduction of the cardiomyocyte 
population (apoptosis) and reactivation of the cardiac fetal gene program, leading all to heart failure. 
Cardiac fibrosis is the excessive build-up of extracellular matrix proteins in activated fibroblasts. This 
increases stiffness in the heart which reduces heart contractility, augmenting the likelihood of heart 
failure. Apoptosis due to cardiac stress diminish the number of fully functional cardiomyocytes in the 
heart [26].  
Changes in the abundancy of one or more miRNAs are related to disease onset in humans and other 
organisms [27]. Modulation of miRNA expression in mice have revealed the great influence of those in 
multiple aspects of the heart physiology, from controlling myocyte growth to regulating contractility, 
fibrosis, and even angiogenesis [28] Moreover, unique expression patterns of miRNAs related with 
pathological cardiac hypertrophy, heart failure, and myocardial infarction in humans and murine 
models of CVD have been identified [27]. Important miRNAS involved in the development of CVD are 
summarized in Table 1 and a detailed review about this topic can be found in the Master thesis of 
Natalia Hernández (2020). 
4.4 miRNAs as Biomarkers 
The features of a perfect biomarker are:  easy traceability, high stability, organ or disease specificity, 
strong robustness and needing only slightly or non-invasive procedures in order to be measured within 
the human body. Clinical biomarkers should desirably not only indicate whether a disease is present, 
but also specify the level of severity and the most suitable therapy [29]. 
miRNAs meet most of these features and therefore could be postulated as ideal biomarker candidates 
for both diagnosis and disease prognosis. miRNAs are actively secreted by tissues and are present in 
most biological fluids which facilitates its detection [30]. Circulating miRNAs present in biofluids are 
stable molecules avidly investigated in biomarker research [13]. Furthermore, certain miRNAs show 




expression analysis have been proved useful to discriminate between diseases otherwise difficult to 
distinguish such as Crohn's disease and ulcerative colitis [32]. Furthermore, different miRNA expression 
patterns have also been identified in short term vs long term glioblastoma survivors patterns [33], 
demonstrating miRNA physiological relevance as biomarkers. 
Table 1. Summary of the main miRNAs whose dysregulation is linked to CVD.  
 
Since miRNA biomarkers could present a potent breakthrough in early disease detection and response 
to therapy progression, many companies are developing screening panels. The first miRNA microarray 
that was approved for use in the clinics was produced in 2012 for cancer detection of uncertain primary 
origin, it allowed identification of 42 different tumours by quantifying expression levels of 64 miRNAs 
with a 90% accuracy [40]. 
miRNA EXPRESSION PHYSIOLOGICAL FUNCTIONCTION PHENOTYPIC OUTCOME  REFERENCES 
miR-1 Downregulated 
Regulates cardiomyocyte hypertrophy 
through repression of hypertrophy 
inducing genes: Calmodulin, myocyte 








regulates cardiomyocyte proliferation and 





Suppression of the BH3-only domain 






Regulates expression of extracellular 
matrix proteins: 
multiple collagens, matrix 
metalloproteinases, fibrillins and elastin 
Increase fibrosis [35] 
miR-34a Upregulated 
Regulates PNUTS and SIRT1 (protect 





Controls hypoxia-inducible factor-1α 
















associated protein 1 (THRAP1) and β-MHC 
(involved in cardiac remodelling) 
Increase cardiac 




protein kinase IIδ, and the cell death 











However, a number of limitations need to be overcome for miRNA to reach further clinical applications. 
Isolation from body fluids (peripheral blood, saliva, urine…) gives poor yields for quantification and 
there is high variability in detection assays due to low inter-platform concordance [41]. Furthermore, 
the use of non-standardised statistical analyses from miRNA clinical testing also increments the 
inconsistency when data of different studies have to be compared. Moreover, genetic variability could 
cause deviations in miRNA expression and function assessment in populations with distinct ethnic 
backgrounds [29].   
Concerning CVD, a new high-throughput miRNA profiling panel that contains clinically relevant miRNAs 
related to cardiac disease, has identify miR423-5p as a biomarker for heart failure. This microarray 
aims to diagnose heart pathologies as well as provide a cardiovascular risk profile evaluation, 
considering that it integrates information from a collection of heart disease related- miRNA [42]. 
4.5 Models to study cardiovascular disease and develop new therapies  
The approval of novel therapies is a long process that starts with drug discovery, including the 
identification of the molecular target and the finding of effective drugs.  Then, once the drug has been 
formulated and tested in vitro, preclinical in vivo testing in animal models is the next step before 
initiating clinical trials in humans. The potential of miRNAs as disease targets has been described in the 
last years, therefore miRNA therapeutics are mainly in the drug discovery or preclinical model testing 
(mice and pig essentially) phases. Only a few of them that have successfully entered in clinical trials 
are linked to CVD, such as LNA antimiR-92a and antimiR-132 (Table 2) [43]. 





The ideal model to study any disease before initiating any human trials should not only precisely 
represent the physiology and biochemistry of such disease in humans but also be inexpensive, easy to 
handle, highly reproducible and ethically approved [44].  
4.5.1 In vivo models (preclinical animal models) 
Murine models are extensively used in pre-clinical trials. They are cost-effective, have shorter gestation 
times and are easier to manipulate in a laboratory environment than large animal models. As a result 
they are more suitable for “high-throughput” studies [45]. Yet, substantial differences in cardiovascular 
parameters such as heart weight, heart rate, blood pressure and the coronary artery system are found 
between rodents and those of bigger animals and humans [43] (Table 3). Thus, their response to 
pharmacological treatments may not be the most reliable outcome predictors and conclusions 
extracted from those trials should be considered carefully [46]. For instance, the coronary circulatory 
system of pigs has no anastomoses between distinct vascular branches, whereas in dogs, coronary 
arteries present several ramifications. Thus, the young human heart may be more similar to the pig 
one, while the older human heart, in case it has a background of ischemic episodes leading to collateral 
growth, may resemble more to the dog one [47]. 
Table 3. Advantages and limitations of the different animal models when compared with humans. 
ANIMAL 
MODEL 
ADVANTAGES LIMITATIONS REFERENCES 
Murine 
models 
 Wide range of transgenic and 
knockout strains 
 Easy to genetically modify 
 Size and structural differences of 
the cardiovascular system. 
 Heart to body mass ratio of 0,55-
0.60 (0,4 in humans) 
 Ten times higher heart rate than 
humans 
 Naturally resistant to develop an 
atherosclerotic lesion 
 Studies in CVD are based on 
genetic modifications, 
pharmacological inducted or 
surgery procedures. They cannot 
mimic the real conditions 
underlying the disease 
[48] 
Dog 
 Electrophysiological system very 
similar to that of humans. 
 Prone to develop atrial fibrillation 
(being the main model in this 
disease) 
 Coronary arteries are massively 
collateralized (not useful for 




 Collateral coronary circulation and 
arterial anatomy very similar to 
human (useful model for 
myocardial infarction) 
 Parameters like heart weight, blood 
pressure, and heart rate are 
comparable to the ones of humans 
 Weight and size of the animal 
 Studies in CVD are based surgery 
procedures or pharmacologically 
induced. They cannot mimic the 








A great amount of studies have not been replicated in larger animal models, generally because of the 
higher associated costs, handling difficulties or limited sampling size [43]. However, data obtained 
from those studies, despite manifesting certain limitations may be more predictive for human CVD 
than those obtain with small animal models, due to higher similarities in cardiac physiology with the 
human body [44].  
Nonetheless, translation of toxicity and effectivity results from small to large animals or humans can 
fail mainly due to physiological differences between models [43] [45] (Table 3). Before initiating a first-
in-human trials, “proof of concept” (solid evidence which demonstrates that is feasible) and safety 
evaluation in large animal models are often mandatory steps [43]. However, several aspects that 
influence CVD such as age, sex, comorbidities, polypharmacy and genetic background of each patient 
cannot be precisely replicated in experimental models and can only be considered and tested in human 
clinical trials with a cohort of patients having the desired characteristics [52].  
4.5.2 In vitro and ex vivo models 
In vitro culture systems have been largely used in CVD research [45][53]. Monolayer cultures like CM-
iPSC, which display most functional characteristics of cardiomyocytes, and are broadly used as human 
in vitro models [54]. However, their immature phenotypes fail to mimic the adult heart functioning 
and cannot model chronic heart disease phenotypes [55]. New ex vivo 3D cultures such as engineered 
heart tissues (EHT) and living myocardial slices (Figure 3) may reflect with higher accuracy how an adult 
heart will behave under certain disease conditions or drugs tested. They would allow to detect 
cardiotoxicity as well as overcome differences in between the different animal species used as animal 
models, rising as intermediate models between in vitro and in vivo models [43]  
EHTs are created from CM-iPSCs cultivated onto scaffolds to generate beating tissues. As described by 
Prondzynski et al., EHTs were a reliable representation of the diseased patients heart, for example if 
the patient has hypertrophic cardiomyopathy, the CM-iPSCs will also share this phenotype [56]. 
Compared with a 2-dimensional cell culture system, EHTs exhibit a more conserved structure and 
mature-like phenotypes which are highly similar to those in adult cardiomyocytes.  
To prepare living myocardial slices, small or large mammalian hearts from commonly used pre-clinical 
models or human hearts coming from both diseased and healthy individuals, are explanted (Figure 3). 
Non-human 
primate 
 Lifespan more similar to humans, 
would allow for Chronic heart 
failure research 
 The most phylogenetically similar 
model to humans (up to 98.77% of 
DNA sequence similarities) 
 Present ethical and financial issues 
 Studies in CVD are based surgery 
procedures or pharmacological 
inducted. They cannot mimic the 






Watson et al created a protocol for the preparation of adult ventricular myocardial slices with a 97% 
preserved cardiomyocyte viability and functionality for up to 1 week [57]. The left ventricles or other 
parts of the heart are then isolated and dissected into small tissue blocks, which are later cut into thin 
slices by a vibratome. Myocardial slices are sections of approximately 100-400 micrometres thick 
which form a 3-dimensional structure composed by the original structure of the tissue where the 
electrical and mechanical connections are conserved. Furthermore, such thickness allows for oxygen 
flow and small compound diffusion preserving the myocardial slice. Drug treatment assays for drug 
screening as well as electrophysiological analyses by adjusting the voltage that stimulates the 
contraction of the myocardial slices, cardiac fibrosis and heart failure trials have been successfully 
performed in myocardial slices [43].  
 
Figure 3. Workflow of  3-dimensional ex vivo models: Engineered heart tissues (EHTs), and living 
myocardial slices. [43] 
Therefore, the model chosen for drug discovery and testing should be one that best mimics the disease 
in humans for all the parameters that want to be measured, since none of the existent animal models 
can completely portrait the multiple pathological outcomes in complex diseases. 
4.6 microRNA-based therapies  
miRNAs unbalance in disease is either caused by a major miRNA overexpression, which will likely cause 
the inhibition of a set of genes, or by a largely diminished expression, that will unleash otherwise 




therapeutic approaches are being considered (Figure 4): miRNA replacement therapy, that will consist 
on the reintroduction of the depleted miRNA in disease, or miRNA silencing, that will lower its 
abundance to physiological levels [58]. 
 
Figure 4. Different therapeutic strategies towards regulating miRNA and mRNA expression. 
Adapted from Bernardo et al. 2015.[26] 
In the miRNA replacement treatment, there are two types of miRNA mimics that can be designed to 
restore normal expression by artificially increasing the endogenous miRNA population [59], [60]: 
 Synthetic mature miRNA molecules that mimics the exact sequence of the inhibited 
endogenous miRNA. 
 Short hairpin RNAs (shRNAs) which are synthetic RNA molecules that before reaching the 
mature miRNA state need to be processed by the endogenous processing machinery of the 
miRNA pathway of the targeted cell.  
In the latter, the fact that an extra step is needed so that the shRNAs would be functional, can minimise 
potential toxicity, since the amount of active mature miRNA will not only depend on the dose 
administered and the delivery vehicle but also on the processing rate [29]. 
However, the world of miRNA inhibitors is much wider [29], going from short, single stranded synthetic 
antisense-oligonucleotides (ASOs) that have high-affinity binding sites in the selected miRNA, to 
miRNA target decoys [61] or cirRNA sponges that can target more than one miRNA at a time (it has 
multiple repetitions of the miRNA binding sites [61]) [62]. The main effect of a miRNA inhibitor is gene 




As it will further discussed below, delivery is a major obstacle for RNA drug development, since 
achieving effective concentrations on the desired area is challenging [58]. On top of that, the 
administration method is another factor that needs to be considered in order to decrease toxicity and 
off-target effects [29].  
The high flexibility of the target binding region (seed sequence) in miRNA is a double-sided feature. It 
allows them to target entire pathways, but, off-target effects can easily take place. Nevertheless, this 
in an issue shared with traditional medications, since even though they are usually designed to target 
a specific protein they interact with others causing adverse reactions [63] 
Although, no miRNA-based drug has still reach the clinic, there are several Phase I and II ongoing clinical 
trials [43] (Table 2). Furthermore, other RNA-based drugs targeting CVD or other heart-related 
pathologies have already been approved by the US Food and Drug Administration (FDA) [64]. The most 
recent example is, Patisiran, a drug based on a small-interfering RNA to treat peripheral nerve disease 
has been recently approved. 
4.6.1 Development of miRNA-based drugs  
4.6.1.1 Bioinformatic analysis for target prediction 
Multiple databases are available to predict miRNA-mRNA interactions. One of the most frequently 
published algorithms or miRNA target detection, TargetScan [63], predicts miRNA gene targets based 
on seed regions binding to mRNA, by computing almost all identified miRNA sequences displayed in 
miRbase (http://www.mirbase.org/).  
These approaches are mainly focused on detecting complementary regions between the 3′-UTR of the 
mRNA and the seed sequence of the miRNA [65]. However, miRNA regulatory networks are extremely 
complex and therefore not completely understood. As an example, high miRNA-mRNA association can 
occur despite poor binding to the seed region [66] and vice versa, high complementarity of the seed 
sequence does not always guarantee that a mRNA is regulated by an specific miRNA[67]. Therefore, it 
is common that predicted interactions have an accuracy rate of approximately 26% [68].  
Another plausible explanation as of why miRNA/mRNA interactions cannot be entirely predicted by 
seed matching in silico is than contextual features should be taken into consideration. As an example, 
mRNA with complex secondary structures may prevent miRNA-mRNA interactions since only a few 
single-stranded regions are accessible. Zhao et al. showed that miRNAs have a greater likelihood of 
binding to 3′-UTR which are thermodynamically favourable, meaning that they have a relaxed 
secondary structure which is highly accessible [69]. In fact, interactions that show low free energy 




accessibility is critical for target recognition and that it should also be considered when analysing in 
silico miRNA-mRNA interactions. 
4.6.1.1.1 From bioinformatic prediction to the clinic 
High-throughput screening together with in vitro validation of bioinformatic predictions have 
accelerated the study of putative therapeutic miRNAs. In vitro cultures of primary cells, immortalized 
cell lines, and iPSC-derived cells are used to validate in vitro interactions as well as therapeutic 
potential of the miRNA mimics and antimirs. Vectors and modified oligonucleotides are employed to 
overexpress a specific miRNA or to silence a specific gene function, disrupting the biochemical 
pathways similar to what occurs under disease conditions when miRNAs are dysregulated[43]. 
Furthermore, an increasing amount of animal models are available to asses in vivo validation. 
Additionally, non-human primate models have been successfully incorporated into preclinical miRNA 
investigations and supported the initiation of clinical trials, such as for the miR-122 repressor, 
Miravirsen, in the treatment of Hepatitis C Virus (HCV)[63] 
 
Figure 5. Processes of noncoding RNA (ncRNA)-based drug development[43] 
In order to develop a new drug therapeutic, several steps have to be followed to jump from the 
bioinformatic studies to the human clinical trial (Figure 5). Here, a practical example is described for 
miR-92a. 
MiR-92a overexpression in in vitro studies in human endothelial cells inhibited the expression of pro-
angiogenic factors and the migration of endothelial cells had been reduced as well as their ability to 
adhere to fibronectin[70]. Furthermore, forced overexpression in zebrafish blocked blood vessel 




In vivo studies with miR-92a inhibitors demonstrated pro-angiogenic effects in acute myocardial 
infarction models in mouse and pig[70], [71] and ameliorated vessel repair after neointimal injury in 
rat [72]. Additionally, a light-inducible antimiR-92a showed effectiveness in increasing angiogenesis 
and wound healing  in db/db mice (a model of diabetic impaired wound healing)[73]. So, since several 
studies proved that miR-92a is involved in the regulation, efforts were made into developing an 
effective antagonist to miR-92a that would serve as a therapy to promote angiogenesis in the heart 
and skin to accelerate healing.  
The pharmaceutical company Miragen proceed with a screening of several locked nucleic acid (LNA)-
modified miR-92a inhibitors, the one that obtained better results in in vitro and in vivo studies turned 
out to be MRG-110. Treatment with MRG-110 showed an upregulated expression of the proangiogenic 
gene ITGA5 (miR-92a target) in vitro in both HUVEC cells and primary human skin fibroblasts and in 
vivo in mouse skin, exhibiting its on-target effects [74]. 
In db/db mice with excisional wounds, MRG-110 was injected intradermally which lead to an augment 
in wound re-epithelialization, a rising in ITGA5 protein expression. Furthermore, no systemic toxicity 
or distal angiogenesis was detected. In a wound healing study performed in normal pigs, MRG-110 also 
increased acute excisional wound healing and angiogenesis without appreciable systemic toxicity[74].  
Since this studies demonstrates that a novel LNA-modified antimiR-92a, MRG-110, accelerates 
angiogenesis and wound healing in compromised and acute wounds in both mice and pigs [75]. It was 
approved for clinical trials in humans, and it is currently in Phase I.  
4.6.1.2 Delivery vehicles 
Lipid bilayers facilitate the passive diffusion of small neutral or slightly hydrophobic molecules, while 
impede large, charged molecules penetration [76]. That is why naked miRNAs are defectively taken up 
by cells due to their negative charge. Furthermore, since the dosage that reaches the target cell is 
difficult to predict, undesired off-target effects are likely to occur (Figure 6). On top of that, they show, 
short half-life when presented naked in systemic circulation, due to rapid degradation by circulating 
nucleases, in contrast with endogenous circulating miRNAs that are transported in exosomes that 






In order to stabilize naked miRNAs, their backbone can be modified introducing chemical modifications 
which will favour carrier-free in vivo delivery [77], as it will be explained in 4.6.2. Nanoparticles are one 
of the most successful approaches used to stabilize the therapeutic miRNA and protect it from 
nuclease degradation (Figure 6). If tissue-directed, they also provide a more specifically high 
concentration delivery at the required action site while not affecting healthy tissue, which should 
increase their therapeutic index [78]. However, one of the main problems that some delivery vehicles 
pose is low miRNA encapsulation efficiency, since they tend to diffuse in the aqueous solution needed 
to prepare the nanocarriers [77]. Recently, a wide range of nanoparticle formulations have emerged, 
being a highly innovative approach that could become an effective option for the therapeutic delivery 
of miRNAs (Table 4). To name a few of this biodegradable and biocompatible particles: organic-based 
lipid nanoparticles (LNPs), extracellular vesicles, bacterial minicells, and nanoparticles derived from 
inorganic materials such as silica, gold and polyamidoamine (PAMAM) dendrimers [79].  






VEHICLE VEHICLE DESCRIPTION MAIN CHARACTERISTICS REFERENCES 
Lipid-Based 
Carriers 
 Amphipathic molecules that 
consist on one or more 
phospholipid bilayers with an 
aqueous core 
 Cationic lipids are commonly used. 
They have a hydrophilic amino 
head group (positively charged) 
that through electrostatic 
interactions spontaneously 
interact with the negatively 
charged phosphate backbone of 
the miRNAs 
 Biocompatible 
 Great transfection efficiency (cell 
membranes are negatively charged) 
 Cell toxicity (strong electrostatic interactions 
compromise the cell membrane integrity) 
 Tend to aggregate (interact with negatively 
charged serum proteins). 
 Immunogenicity cases have been reported 
(combination with neutral lipidic molecules 






 Can be composed of either natural 
(e.g chitosan and hyaluronic acid) 
or synthetic materials (e.g PEI and 
PLGA) 
  All of them contain amine groups 
that interact with the phosphates 
present in nucleic acids 
 Natural polymers easily and compactly hold 
nucleic acids. They display high 
biocompatibility and biodegradability. They 
can be modified to ameliorate miRNA 
release efficiency. 
 PEIs has high transfection efficacy, but also 
high toxicity (can be avoided by adding 
chitosan and polyethylene glycol (PEG)). 
Non-biodegradable. 
 PLGA is biocompatible and non-cytotoxic. 
Degradation rate varies depending on 





 Endogenous particles essential for 
cell-to-cell communication whose 
content is highly dependent on the 
cell type. 
 Distinct sizes and different biological origin. 
 The main subtypes are exosomes (30–120 
nm), microvesicles (100–1000 nm) and 




 Gold, calcium phosphate, silica 
and iron oxides forming particles 
 High biocompatibility  
 They are usually modified to facilitate 
miRNA entrapment and prevents 
nanoparticle aggregation and miRNA 
degradation  
 Conjugated with antibodies, or combined 





 Anucleate nanoparticles that 
come from inhibiting cell division 
genes in parental bacterial cells at 
partition time 
 Average 400 nm in size 
 Conjugated with specific antibodies to target 
a specific organ-tissue 
[92] 
Microbubbles 
 Albumin coated microspheres 
filled with the miR therapeutic 
and gas that release their content 
when ultrasounds are applied at 
the target site 
 Non-invasive technique that allows specific 
delivery of miRs therapeutics to the heart 
[93]  [76]. 
Viral vectors 
 Adeno-associated virus (AAV) 
vectors, which allow 
encapsulation of nucleic acids up 
to 4.5-5kb 
 Higher safety profile than other virus-based 
vectors, while maintaining high 
transduction efficiency on several tissues. 
 AAV9 is cardiac specific (supposedly has 
cardiac tropism). 
[94] 






Different administration routes can be used to efficiently deliver the miRNA therapeutic to the target 
organ or tissue. Both local and systemic delivery of the miRNA-drugs are considered [76]: 
 Systemic delivery: nanoparticles and vesicles are modified with tissue-specific ligands to 
enhance delivery to target tissue and subsequent uptake by receptor-mediated endocytosis. 
They are directly injected in the systemic circulation. 
 Local delivery: in case of heart-related therapies, intracoronary injection or intramyocardial 
injection can be used in order to inject miRNA therapeutics locally [80], [81]. Nasal 
nanoparticle delivery has been also tested in case of brain delivery [82] and heart delivery [83] 
in mice. 
Local injection in the heart produces higher transduction rates and diminish off-target events. 
However, efficient diffusion of the therapeutic through the myocardium is still a challenge. 
Furthermore, local injection is coupled with electromechanical mapping and/or positron emission 
tomography to analyse blood flow in the targeted area, allowing for extremely precise administration 
and consequently achieving high efficiency administration around the site of injection.  
Systemic administration of miRNA mimics and inhibitors, apart from being expensive, since high 
amounts of the therapeutic agent are needed, it demonstrates low efficacy on in vivo trials [76]. 
Another important drawback is an increasing chance of potential side effects to occur, since one 
miRNA usually has multiple targets, that might have different or even opposite functions depending 
on the organ or cell type [76]. For instance hsa-miR-24-3p shows divergent effects when expressed in 
vascular (promotes endothelial cell apoptosis and inhibits angiogenesis after ischemia) [84] or cardiac 
cells (apoptosis inhibition of cardiomyocytes in mice) [85]. This suggest that, independently on the 
administration, a tissue- and/or cell-specific delivery might be desirable. 
A strategy to overcome undesired effects in systemic deliveries is the use of tissue-directed 
approaches. Recently many strategies are being exploited to improve targeting cardiac-specific uptake 
of the delivery vehicles. Complete antibodies, Antibody Fab fragment, oligonucleotide aptamers or a 
targeting peptide are amongst the most interesting targeting options [86]. Another one that has 
previously been treated is the microbubbles mediated by ultrasounds delivery of the therapeutic 
miRNA. Encouraging results have been also observed with antibodies, cardiac-targeting peptides and 





4.6.2 AntimiRNAs therapies 
4.6.2.1 Antisense oligonucleotides 
Antisense oligonucleotides (ASOs) have been used for more than 40 years to silence defective mRNAs 
[95]. Recently, they have turn out to be an essential tool to target miRNAs. However, the effects 
observed when targeting miRNA differ from those that take place when targeting mRNAs: ASOs are 
believed to silence the miRNA in an RNase-independent manner, mainly by steric blocking, while in 
case of mRNA the degradation is RNase-dependent [96]. 
ASOs should be designed so that they have a high miRNA binding affinity while efficiently decreasing 
the amount of the target miRNA. Low or non-toxicity and lack of additional side effects are also 
required. The binding affinity is a parameter related to the stability of the ASO-miRNA duplex, and 
therefore is measured by the melting temperature (Tm) of the oligonucleotide. Higher Tm values 
indicates a stronger duplex (more energy is needed to disrupt the binding) [96].  
Non-modified ASOs as composed only of DNA bases are very susceptible to be degraded by nucleases. 
Therefore, extracellular and intracellular stability (resistant to nucleases) is also essential for the ASOs 
in order arrive fully functional to its tissue or cell target, where the miRNA that needs to be silence is 
[97] 
Chemical modifications to ameliorate binding affinity and nuclease resistance are mostly introduced 
in the sugar ring (usually at the C2′ position) and/or in the backbone of the ASO (Figure 7). The latter 
consist on internucleotide linkage adjustments or substituting the entire backbone structures for a 
construction analogous to the DNA [98]. The properties of each modification have been reviewed by 







Figure 7. Chemical modifications applied in the ASOs design. Unmodified nucleotides – DNA: 
deoxyribonucleic acid, RNA: ribonucleic acid; Sugar modifications – 2′-OMe: 2′-O-methyl, 2′-F: 2′-
fluoro-RNA, LNA: Locked Nucleic Acid, UNA: Unlocked Nucleic Acid, and 2′-MOE: 2′-O-methoxyethyl; 
Backbone modifications – PO: phosphodiester, PS: phosphorothioate, PACE: phosphonoacetate, PMO: 
Phosphorodiamidate Morpholino Oligomers, and PNA: Peptide Nucleic Acid. In red is highlighted the 
site and the type of modification [96]  
ASOs composed by, 2′-MOE and 2′-OMe sequences mixed with PS or PO backbones, were studied to 
prove to their potency to repress miR-21 during a sustained period [99]. miR-21 is upregulated in 
hearts from patients that present severe heart failure and in fibroblasts of failing mouse hearts, but its 
role in cardiac remodelling is still not defined, since genetic suppression does not change the 
pathological cardiac response to pressure overload [26]. The most frequently used chemical 
modifications for anti-miRNA therapeutics are LNA, 2′-F-RNA, 2′-OMe, PNA, and PMOs. 
Additional molecules can be linked to the ASOs so that uptake, half-live or delivery are improved when 
administered in vivo, since most of these molecules present enormous difficulties to diffuse across cell 
membranes. One of the most popular organic compounds that is added is a cholesterol molecule at 
the 3′-end. ASOs with a cholesterol modification are denominated AntagomiRs [100].  
Finally, it is important to highlight that ASOs containing unmethylated deoxycytidine-deoxyguanosine 
(CpG) dinucleotides motifs are likely to activate the immune response in mammalian systems [101]. 
Therefore, avoidance of this type of construct is recommended, especially when the ASO is being 
designed for in vivo testing. 
A few examples of miRNAs that can be targeted by ASOs are summarise in Table 5. miR-15a and miR-
15b showed an upregulation in post-ischemic HF models, which was correlated with increasing 




upregulated with age in a mouse model of aging, furthermore, miR-21 has demonstrated to have 
profibrotic effects provoked by the activation of the  ERK–MAP kinase pathway in cardiac fibroblasts  
during injury [103].  miR-34a is involved in both cardiac and vascular aging, being a promising target to 
design therapeutics to  treat CV aging [104]. Inhibition of three miR-34 family members (miR-34a, -
34b, and -34c) has demonstrated to ameliorate cardiac dysfunction in mouse models of HF [105]. Callis 
et al., discovered that when miR-208a is upregulated it contributes to cardiac hypertrophy, and 
disturbs electric conduction leading to arrhythmias in mice [106]. miR-328, is upregulated in AF which 
is linked with a decrease in L-type Ca2+ channel density, inducing atrial electrical remodelling. Delivery 
of antagomiR against this miRNA was able to revert the arrhythmogenic phenotype  [107]. 
 
Table 5. Summary of the main ASOs preclinical studies used for cardiovascular disease. i.v 














 in vitro: cardiomyocytes 
show resistance to hypoxia-
induced cell death 
 in vivo (mice and pig): 
Effective repression of miR-
15 levels 
 in vivo (mice): infarct size 
reduction and cardiac 
function improvement  
[108] 






 Inhibition of ERK-MAPK 
signaling pathway 
 Interstitial fibrosis is 
reduced, and normal 
cardiac function restored 
[109] 
miR-21 
Pigs that underwent 
transient 
percutaneous 





 Cardiac fibrosis and 
hypertrophy are diminished 




Mice in which TAC 
was active for 3 
months  
Antagomir 
Daily tail vein 
injection for 3 
days and 3 
extra injections 
once a week 
for 3 weeks 
 De-repression of SERCA2a 





MI and TAC mice LNA 
daily s.c. 
injection for 3 
days 
 Upregulation of genes 
linked to cell survival, 
contractile functions and 
angiogenesis.  
 Pathological left ventricular 
remodeling is diminished 
 95% knockdown in the 








Whereas the rest of the methods to control miRNA expression focus on targeting the dysregulated 
miRNA, BlockmiRs functions protecting the mRNA from being degraded by miRNAs [26]. 
BlockmiRs are steric blockers that interact with the mRNA at the area where the miRNA is supposed 
to bind, therefore, blocking its access and impeding its down-regulatory function. This method of 
modulating mRNA expression combined with miRNA sponges, increases expression of proteins 
encoded in the mRNA whose expression was repressed. Nonetheless, it has low gene-specificity 
because the seed sequence or the 3’UTR target sequence can be common in many genes [96]. 
The unique and more useful characteristic of the blockmiRs is that while protecting a specific mRNA of 
being downregulated, the miRNAs targeting this mRNA can still regulate its other mRNA targets [26]. 
However, this technology has not been applied yet to target miRNAs related to CVD. 
miR-92a 





Local (with a 
catheter) or i.v 
 Reduction in miR-92a 
expression is achieved with 
both administration 
methods in the infarct area 
 Reduction in the infarct size 
is only seen in local delivery. 
It led to a boost in the 
ejection fraction and lower 





mouse models of 
limb ischemia and MI 
Antagomir i.v 
  Blood vessel growth is 
boosted  





induced heart failure 





 Pathological myosin 
switching (from Myh6 to 
Myh7) and cardiac 
remodeling are inhibited 
 Enhanced cardiac function  







LNA i.p.  
 Transition of adaptive to 




Mouse model of 
heart failure 
(calcineurin 






i.p on three 
consecutive 
days 
 Recovery of physiological 
expression of Dyrk1a 
 Reduction in nuclear NFAT 
activity  
 Inhibition and reversion of 












 Atrial fibrillation is 






miRNA-sponges, act as competitive inhibitors, since they are mRNA molecules with multiple binding 
sites (around 4 to 12) for the target miRNA that will sequester the upregulated miRNA. Thus, the 
endogenous target mRNA will not be repressed and will execute its function normally [118]. Increasing 
the number of binding sites augments the sponge activity, this is a crucial step if saturation occurs, the 
RNA is likely to be degraded. Adding spacers between the binding sites enhances the binding 
likelihood, and reduces the formation of RNA secondary structures [119]. 
miR- sponges within the AAV6-CMV cassette are not expected to exhibit a functional effect in other 
tissues, since they seem to have  heart tropism [120]. Hereafter, a few examples of miRNA sponges 
against miR-21, miR-34a and miR181 are exposed (Table 6). 
microRNA-21 (miR-21) controls vascular smooth muscle cell (VSMC) proliferation and phenotype 
transformation. Therefore, AAV-mediated miR-21 sponge was developed to supress  VSMC 
proliferation in vitro and neointimal formation in vivo (rats), to diminish the chances of vein graft 
failure, an important complication of cardiovascular surgery [121]. 
Inhibition of miR-34a or the miR-34 family with miRNA sponges show cardioprotective results in mice 
hearts after heart injury. However, this inhibition shows no appreciable phenotypic effect in control 
mice [118]. Nonetheless, chronic inhibition of miR-34 would enhance tumorigenesis [122] 
The AAV6-CMV-miR-34 15-nucleotide sponge in vitro exhibit an approximately ∼40–50% knockdown 
of miR-34a, -b, and -c expression when treated cells were compared to control. However, in vivo 
experiments showed that neither AAV6-miR-34-sponge 15 nucleotide nor its 8 nucleotide version were 
able to supress miR-34 family in the heart [118]. 
miR‐181 family regulates cytoplasm and mitochondrial genes linked to oxidative stress. For instance, 
miR‐181a/b regulates PTEN expression (cytoplasm) and miR‐181c controls mt‐COX1 (mitochondria) in 
cardiomyocytes. Downregulating miR‐181 family expression in the heart using AAV6 delivery with a 
miR-sponge showed how different family members exert its function in distinct cellular compartments. 
Reduction of miR‐181c in the mitochondrial compartment exhibit cardioprotective effects against 
oxidative stress (aging hallmark), whereas suppressing miR‐181a/b in the cytosol has severe effects 
during ischemia/reperfusion injury due to overproduction of ROS. This miRNA family pose a perfect 
example of how finely tuned miRNA functions are, and how important is knowing all the functions to 






Table 6.  Summary of the preclinical studies applying miRNA-sponges technology to CVD. 
i.v:intravenous injection, nt: nucleotide 
4.6.2.4 Tough decoy (TuD) 
TuDs are synthetic molecules formed by a long RNA hairpin of approximately 60 base pair with an 
internal loop that has two miRNA binding sites (Figure 8). It acts as a competitive inhibitor preventing 
endogenous miRNA binding to target mRNAs[61]. 
As we can observe in the figure 8 ,TuD present several distinct regions: an 18-bp long stem, two miRNA-
binding sites, a 26-nt long stem-loop that links the miRNA binding sites and four 3-nucleotide linkers 
(2 on each chain) defining the two miRNA-binding sites and separating them of the stem-loop and the 
stem. Usually, in each of the miRNA binding sites, a 4-nt long mismatch is added in between 




In vitro: Primary rat 
VSMCs 
 
In vivo: Male SD rats 
2 tandem repeats of 20 
nt, with a mismatch 
between positions 9-12, 
separated by a short 4 
nt spacer 
Vein graft 
















In vivo: adult mice 
C57BL/6 or FVB/N 
background 
Four tandem repeats, 
each of 15 nt long, of 
either the miR-34a, miR-
34b, and miR-34c 
binding sites. 
 
In vivo: i.v 
Adeno-associated virus 






In vivo: adult mice 
C57BL/6 or FVB/N 
background 
Eight tandem repeats of 
the miR-34 seed region 
(8 nt long) 
 
In vivo: i.v 
Adeno-associated virus 










10 tandem repeats 
complementary to the 
seed sequences of miR‐
181 family 
Transfection 
The sponge sequence is 








nucleotides 10 and 11 from the 5′ end of the miRNA to avoid perfect-base pairings with miRNAs. Thus 
for, preventing the cleavage of the miRNA-binding site [118] 
A few examples of TuD that target miRNA related to CVD are shown in Table 7. When studying, the 
effects of TuD-miR-34a in the heart, the results obtained where the same as with the previously 
exposed miR34-sponge approach: despite being taken up by the cardiomyocytes in the heart, no 
significant inhibition of miR-34a or any of the family members was achieved. These results are contrary 
however to the high inhibition was achieved with LNA-ASOs technology [36].  
Table 7. Summary of the preclinical studies applying TuD technology to cardiac disease. i.v 
(intravenous injection) 





In vitro: H9c2 cells 
 
In vivo: pressure-overload murine HF 
model 
In vivo: single i.v dose 
 
 AAV9  
[61] 
miR-34a 
In vivo: adult mice C57BL/6 or FVB/N 
background 
 
In vivo: single i.v dose 
AAV6 [118] 
miR-146a 
In vivo: Wild-type mice subjected to 
TAC surgery (leads to pressure 
overload) 
 
In vivo: single i.v dose 
AAV9 [124] 
 
miR-25 regulates Serca2a activity, which is in charge of calcium uptake during excitation-contraction 
coupling in cardiomyocytes. miR-25 upregulation, disrupts calcium uptake and contributes to heart 
failure [111]. AntagomiRs, designed to diminish miR-25 have already proven to be effective, however 
in this case TuDs are studied since they are highly resistant to endonucleolytic degradation and present 
improved miRNA binding affinity [61]. The AAV9 TuD exhibits selective inhibition of miR-25 both in vivo 
and in vitro. In addition, miR-25 TuD expression in the heart lasts longer and therefore has a more 
powerful inhibitory effect when compared to the antagomir-25, previously created. Furthermore, 
Western blot analysis shows that miR-25 TuD achieves almost a complete restoration of the 
physiological Serca2a levels, ameliorating cardiac dysfunction and fibrosis [61]. 
miR-146a is expressed in fibroblasts after HF and targets SUMO1, which diminishes SERCA2A 
SUMOylation, inhibiting cardiomyocyte function both in mice and humans failing hearts [124]. mir-
146a is secreted from activated fibroblasts inside an extracellular vesicle that is taken up by 
cardiomyocytes. Surpressing miR-146a activity through TuD improves cardiac contractile function by 
restoring SUMO1 levels in mice with pathologic cardiac hypertrophy [124]. 
However, it is important to notice that downregulation of miR-146 might not always be beneficial, 




miR-146 is upregulated in a cellular model of endothelial senescence [125], others affirm the contrary 
[126]. Furthermore, miRNA-146a has anti-inflammatory properties and it is widely expressed in 
immune cells. In fact, a protocol to deliver miR-146a directly to the atherogenic lesion to diminish 
macrophage recruitment and atherosclerotic plaque size in mice was reported [127]. 
4.6.3 miRNA mimic-based therapies 
miRNA mimics are described as oligonucleotides that act in the same way than the endogenous 
miRNA. Therefore, miRNA mimics bind to target mRNA leading to its translational repression and or 
degradation suppression [36]. In the table 8, a list of miRNA mimics investigated in CVD is shown.  
MiRNA mimics have been tested to restore the correct regulation of cardiac functioning by increasing 
the amount of a determined miRNA that it is downregulated and causing a heart-related pathology. 
Among them, miR-19a-mimics are useful to induce regeneration in the myocardium after infarct. 
Furthermore, taking into account that miRNA-19 is severely downregulated in an aged HF-prone 
mouse, findings that were corroborated in human samples, this mimic could also help to induce cell 
renovation and decrease apoptosis associated with aging. miR-199a seems to be extremely 
downregulated in cardiomyocytes when the amount of oxygen available is reduced. This reduction 
results in an upregulation of its target, the hypoxia-inducible factor (Hif)-1α. Therefore, by delivering 
a miR-199a-mimic during hypoxia conditions Hif-1α expression is repressed, and p53 is stabilized, 
reducing apoptosis [37]. 
Table 8. Summary of the preclinical studies with miRNA replacement technology in cardiac 
miRNA 
Target gene and 
Physiological 
function of the miRNA 
Model Mimic effects Administration References 
miR-19a 
 Controls PTEN, gene 
involved in cell 
proliferation and 
apoptosis 






right after MI as 








 Promote cardiac fibrosis 
by targeting mitogen-
activated protein kinase 
(MAPK) signaling 
 Regulates VSMC 
differentiation in response 
to BMP signaling 
 Regulates magrophage 
activation 
Mice  Cardiac 
macrophages at 





 Angiogenesis is 
enhanced and 
hypertrophy, 










reduced in the 
myocardium. 
miR-29 
 Downregulated in fibrotic 
disorders 
 Controls collagen genes 
(COL1A1, COL1A2, 
COL3A1) and extracellular 
matrix proteins 
expression, such as fibrillin 
(FBN1) and elastin (ELN1) 
Mice  Decreased 
collagen 
expression  









 Targets the angiogenesis 
related protein Spred1, a 
regulator of the MAP 
kinase signaling 
downstream of VEGF and 





2a (PIK3R2a), (PI3K 
signaling) 
In vitro  Promotes 
angiogenesis 
 Attenuation of 











 Downregulatedin cardiac 
myocytes during oxygen 
deprivation. This induces 
its target genes: hypoxia-
inducible factor-1α (HIF-
1α) and sirtuin (Sirt 1), and 
subsequent activation of 
hypoxia-triggered 
pathways. 
Adult Mice Restoration of 
physiological miR-199 
levels inhibits HIF-1α 
expression and 
its stabilization of p53, 
a tumor supressor 
responsible 
for sustaining the 
genome integrity, 











 Downregulated after birth 
 Target genes involved in 
the Hippo signal pathway 
(Mst1, Lats2, Mob1b) 









 Promotes cardiac 
regeneration and 
improved 






 Associated with heart 
regeneration through 
modulation of Homer1 
and Clic5 
Adult Mice  Cardiomyocyte 
proliferation 
 Improved cardiac 
function 













4.6.4 Current state of miRNA-based drugs and repurposing to treat CV 
Over the past few years there has been a great increase in the miRNA research field for both diagnostic 
and therapeutic purposes. Still, no miRNA therapeutics have been approved by the FDA nor by the 
EMEA (European medicines agency) for clinical use [134] 
One of the most promising miRNA-based drugs was MRX-34 (a liposome-based miR-34 mimic) 
designed to treat liver cancer, certain solid tumours or hematologic malignancies. It entered clinical 
trials in 2013 (NCT01829971). However, the study had to be terminated at phase 1 since severe 
immune-related adverse events occurred [134]. Nonetheless, encapsulating this miRNA in highly 
specific nanoparticles that would only deliver it to the desired area and adding molecules that would 
hide the mimic from the immune system could help to increase its therapeutic potential, avoiding 
adverse reactions. 
Thus far, out of all active clinal trials with either miRNA mimics or anti-miRs, only two target the 
cardiovascular system. One of them, which is now recruiting candidates for a second phase 1 clinical 
trial (NCT 03603431), consist on MRG 110, a locked nucleic acid (LNA)-modified antisense 
oligonucleotide that is thought to have a pro-angiogenic effect by directly inhibiting miR-92a. This 
would accelerate wound healing as a result of increasing blood flow in the affected area 
(https://clinicaltrials.gov/). The other compound (CDR132L) is an antimir directed against miR-132. 
This miRNA mediate cardiac hypertrophy via FOXO3 downregulation and autophagy. CDR132L is in 
Phase Ib. 
However, some of the drugs that are in clinical trials could be successfully repurposed to target the 
cardiovascular system. For example, LNA-antimiR-155 (Cobomarsen) indicated for blood cancer could 
be very useful to restore cardiac normal functioning since in vivo studies have showed that inhibiting 
miR-155, could ameliorate cardiac inflammation. Another example, could be miRNA-29b mimic 
(Remelarsen) which targets cutaneous fibrosis, since miR-29 family members (miR-29a, miR-29b, and 
miR-29c) are downregulated in fibrotic disorders leading to increased levels of essential extracellular 









5. MATERIALS AND METHODS 
5.1 Sequence Analysis and Bioinformatic tools 
The BIO-AGEmiRNAs that have been selected for this study are: miRNA 3916, miRNA 4435 and miRNA 
24-2 (Table A1). All of them were upregulated with increasing biological age in human LV [15] 
Perl Primer on-line software (Open-source PCR primer design, Sourceforge) was used to design the 
DNA oligonucleotides used as PCR primers (Table A2). The oligonucleotides were designed to amplify 
the pri-miRNA DNA sequence plus 250 flanking nucleotides to facilitate folding. 
5.2 Bacteria and culture medium  
Chemically-competent Escherichia coli, strain DH5α, were used for miRNA cloning and recombinant 
DNA vector amplification purposes. 
Bacteria cultures in liquid media utilized Luria Bertani (LB) medium (MP Biomedicals, 3002022) with 
100 μg/ml de Ampicilin (Sigma Aldrich, A9518-5G). In case of solid culture, LB-agar plates (Nzytech, 
MB11801) also supplemented with 100 μg/ml Ampicillin were used. Bacterial cultures were incubated 
O/N at 37˚C. 
5.3 Cloning Vectors  
The plasmid used to clone the miRNAs of interest, the pZ:F3-P TetOn 3f-tdT-F (V5)[17], was available 
at BSICoS. V5 is composed by an Ampicillin Resistant gene (allows selection of transformed bacteria), 
a Puromycin resistance gene (allows selection of transfected iPSCs) and inducible tdTomato 
fluorescent protein (tdT). TdT expression is controlled by a Tetracyclin Response Element (TRE) in a 
TetON set up: binding of the reverse tetracycline transactivator (rtTA) protein to tetracycline allows 
activation of the TRE promoter. We can also find two pairs of cHS4 insulators that isolate the whole 
transgene expression from the surrounding environment (Figure A1). 
5.4 Polymerase chain reaction (PCR) 
The miRNAs of interest were amplified by PCR in two different samples of human genomic DNA: D086 
(Hek293) and D101 (White blood cells), using a high fidelity Taq DNA polymerase, Phusion Taq 
(Thermo, F-530L), following the protocol recommended by the manufacturer and specific 
oligonucleotides and amplification programs for each amplicon (Table A2 and A3). The reactives used 




5.5 Agarose gel electrophoresis 
To assess PCR results or restriction patterns, they were run on 1-1,5% agarose in 0.5x TBE buffer 
(50mM Tris, 45mM Boric Acid and 0.5mM EDTA) (Invitrogen, 15581044). To purify fragments from gel, 
the bands of the appropriated molecular weight were excised. 
In all cases, gels were stained with Green Safe Premium 1:10000 (NZYTech, MB18081). The 
electrophoresis were performed at 135 volts. The samples were loaded into the wells after being mixed 
with loading buffer (30% glycerol, 0.25% bromophenol blue) (Invitrogen,10816015), except when 
digestion buffer (Red Anza buffer(Invitrogen,INVGN02028)) or NZYtaq II 5x gel load reaction buffer 
(NZYtech,17111) were used. 
A molecular weight ladder,1 Kb Plus DNA Ladder (Invitrogen, 10787-018), was loaded to compare with 
the molecular weight of the samples. The iBright CL1000 (Invitrogen) was used to image the agarose 
gels.  
5.6 Nucleic Acids purification 
Purification of DNA fragments derived from excised agarose gel bands or directly from the PCR product 
was performed using NZYGelPure (NZYtech, MB01102), following the recommended instructions by 
the manufacturer.  
Extraction and purification of plasmids was carried out with NZYSpeedy Miniprep Kit (NZYtech, 
MB21002) and Purelink HiPure Plasmid Midiprep Kit (Invitrogen, K210004). The first one was used to 
obtain a small quantity of the vector that could be prepared for sequencing. The second one, to obtain 
enough amount and of high quality plasmids, for storing and further experiments. 
5.7 Cloning 
5.7.1 Vector and insert digestion  
Digestion mix for cloning purposes contained 2 μg of the DNA insert and 1 μg of the corresponding 
DNA of vector, as well as 0,5-1 U/μl of each restriction enzyme (Table A6) in the appropriate digestion 
buffer. The digestion mixes were incubated at 37˚C for 4 hours followed by an inactivation step at 80˚C 
for 20 minutes and then run on gel and purified according to section 5.6. 
5.7.2 Ligation 
The digested products were purified as indicated previously and quantified using a 
spectrophotometer. The ligation mix contains 25 ng of the digested vector, the adequate amount of 




Biolabs, M0202A) and 20 U/μL de T4 DNA ligase (New England Biolabs, M0202L). The total volume of 
the mix was 10 μl. 
The mixture was incubated at 22˚C for 1 hour, followed by an inactivation step of 65˚C for 10 minutes. 
Each ligation reaction had its negative control sample that included only the vector (without insert), 
so that the amount of undigested or re-ligated vector could be determined. 
5.7.3 Transformation of DH5α competent bacteria 
Twenty five μL of DH5α competent bacteria were thawed on ice and incubated on ice for 30 minutes 
with 3 µL of the ligation reaction. Next, heat shock was induced at 37˚C for 60 seconds, followed by 5 
minutes in ice. Subsequently, 500 μL of SOC medium were added and tubes were incubated at 37˚C 
for 1 hour at 250 rpm. Finally, 200 μL of the transformed bacteria were plated in LB-agar culture plates 
containing 100 µg/ml ampicillin. After incubation O/N at 37ºC, individual colonies of ampicillin 
resistant bacteria could be observed and numbers in each condition annotated.  
5.7.4 Screening of recombinant colonies 
5.7.4.1 Colony PCR  
Colonies of interest were replicated on a clean agar plate (control plate) and in parallel, bacterial 
lysates were prepared by inoculating each of these colonies in 12 μL of miliQ water. Osmotic pressure 
together with the initial PCR denaturation step releases the bacterial nucleic acid content. Separately, 
the NZYTaq II DNA Polymerase mixture was prepared (Table A5) using specific primers for each gene 
(Table A2) and specific amplification programs (Table 3A). Recombinant colonies were determined by 
the presence of specific size amplification products on agarose gels after electrophoresis. 
5.7.4.2 Enzymatic digestion 
Verification of colony PCR results or screening without it (when no colonies grew in the ligation 
negative control plate) was carried out by enzymatic digestion as indicated in section 5.7.1 with 
approximately 300 ng of plasmid DNA. The enzymes used in this work are included in Table A6. 
5.8 Sequencing 
One or two recombinant clones were confirmed by sequencing using the Sanger method (STAB VIDA) 
using three oligonucleotides to cover the whole cloned region (Table A7). The sequences obtained 




5.9 Cell culture 
Hek293 cells culture medium is composed of DMEM (Biowest, S18240L0093), with 10% FBS (Thermo 
Fisher Scientific, 10270098) and 1% penicillin and streptomycin (Thermo Fisher Scientific, 15140122). 
A vial of approximately 10⁶ Hek293 cells was thawed by immersion in a water bath at 37˚C. The cells 
were transferred to a clean 15 mL tube and 9 mL of complete medium were added dropwise. To 
remove traces of the DMSO (cryoprotectant toxic for the cells at room temperature) cells were 
centrifuged (300 xg, 5 min) and resuspended in 15 mL of fresh medium so that they could be seeded 
into a 75 cm2 culture flask. The medium was refreshed every two days by removing it, washing it with 
PBS and adding fresh medium. The culture was kept in flasks of 75 cm2 or 25 cm2 according to the 
experimental needs. 
When the cell monolayer in the flask reached a confluence close to 100%, the cells were diluted and 
reseeded in another flask to allow further proliferation. For transfection, cells were counted in a 
hemocytometer taking 15 µl of the cell suspension and mixed with 15 µL of Trypan Blue (Thermo fisher, 
15250061), a viability dye. Cells were seeded at 250000 cells/well in 12 well plate for transfection. 
5.10 Transfection 
Transfection was performed with Lipofectamine 2000 Reagent (Invitrogen, 11668027) 24h after 
seeding the cells, following the manufacturer's instructions. Briefly, for each well, 1 µg of the plasmid 
containing the miRNA to be tested was mixed with 54.7 µl Optimem (Thermo Fisher Scientific, 
31985062) (tube A). The same amount of Optimem was mixed with 3,28 μL of lipofectamine (tube B). 
Subsequently, the contents of tube A were poured into tube B and incubated 5 minutes at room 
temperature. 
109 μL of the tube A + tube B mixture were added per well. Since each condition was tested in 
triplicate, these quantities were adjusted to create a common mix for all the replicates. Transfection 
was performed using V39 vector. 
5.10.1 Assessment of the transgenic miRNA expression 
Doxycycline at 1 µg/ml per well was added to the cultures 24 hours post-transfection. After 24 
additional hours, the cultures were visualized and imaged under a fluorescence microscope (Nikon, 
TS2). Next the cells were lysed for total RNA extraction, including small RNAs, using the RNA lysis buffer 
of the extraction kit RNA/DNA purification kit (Norgen biotek corp., Cat.48700). Total RNA was isolated 




Retrotranscription of miRNAs was carried out with qScript microRNA cDNA Synthesis Kit (Quanta 
Biosciences, 95107-025) using 200 ng of RNA according to the recommendations of the manufacturer.  
qPCR was done using Power SYBR Green PCR MM (Thermo, 4368706) and primers for miR-4435 and 
RNU6 (normalizer gene) (Table A8). An RT negative control (without retrotranscriptase) and a sample 
without template were used as negative controls in qPCR. 
6. RESULTS 
6.1 Creation of a miRNA inducible expression vector. 
The scheme presented in Figure 9, grafically explains the steps that have been followed in order to 
create a new vector in which expression of the miRNA of interest can be induced by doxycycline. This 
process is detailed in the following sections. 
 
Figure 9. Workflow scheme of the creation of a new vector. The different cloning steps as well as the 
composition of the different inserts are described. 
6.1.1 Cloning the miRNA of interest in V5  
6.1.1.1 miRNA amplification 
PCR amplification of miR-4435, miR-3916, miR-24-2, was only succesful for miR-4435 (Figure 10). 




or adding DMSO, in order to achieve amplification of miR-24-2 and miR-3916, but they were 
ineffective. Therefore, in order to proceed with the study of those miRNAs in a future work, they have 
been synthesized, and during this study only miR-4435 will be analysed. 
 
Figure 10. PCR amplification of miRNAs of interest. Amplifications of miR-4435, miR-3916, miR-24-2. 
The upper index on top of each sample name corresponds to the two different DNA samples used, 
being 1 referred to D86 and 2 to D101. CN: Negative Control (one for each PCR reaction). The bands 
observed corresponds to the miR-4435 amplicon at the expected molecular weight (approx. 820pb). 
MW ladder: Molecular weight ladder. 
6.1.1.2 Cloning of mir-4435 in the inducible expression vector 
In order to clone the miR-4435 in the destination vector V5, both V5 and the purified PCR product, as 
well as a positive digestion control (V1) were digested with MluI. Then, V1 digestion product was 
analysed by gel electrophoresis as a positive control to confirm that MluI succesfully digested the 
samples, as observed in Figure 11. After digesting with the restriction enzyme, vector V5 had to be 
dephospohorylated using alkaline phosphatase to avoid religation. Ligation was set up and the 














Table 10. Ligation results. Two plate replicates were made of each one of the ligation reactions, the 
first column corresponds to replicate one in both 3:1 and 5:1 ratios, and the second column to replicate 








Figure 12. Colony PCR results. Amplification of recombinant plasmids in bacterial lysates resulted in a 
fragment of approximately 820 bp, highlighted with yellow boxes. MW: molecular weight DNA ladder 
(Kb). 
These positive clones were further confirmed by restriction digestion with NcoI and two were 
recombinant since their restriction patterns matched those generate in silico.  
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Figure 13. Identification of recombinant colonies by restriction digestion. Numbers on top of the wells 
correspond to the colony number. MW: molecular weight DNA ladder(Kb). 
 
Clones 12 and 29 were sequenced to definitively confirm the correct insertion of mir-4435. 
Once the sequence was verified, the recombinant colonies were cultured in 100 ml of LB-Ampicillin so 
that enough vector could be prepared. The vector was confirmed one more time by enzymatic 
digestion with NcoI before proceeding with transfection. The new vector was assigned the code V39. 
6.1.1.3 Analysis of the expression of the mir4435 inducible expression vector (V39) 
HEK-293 cells were seeded in 6 wells of a 12-well plate. After 24h they were transfected with V39. 
Induction of mir-4435 expression was performed by adding doxycycline 24h post-transfection. The 
expression of the tdT reporter upstream of miR-4435 RNA sequence was confirmed by fluorescence 
microscopy (Figure 14). 
 
Figure 14. Transfection of Hek293 with V39. Hek293 were transfected with V39 and treated with (left 






As it can be observed in figure 14, where doxycycline was added, tdT reporter expression is strongly 
induced. A certain amount of leakiness is observed in Hek293, likely due to the high transfection 
efficiency in these cells that can lead to multiple plasmid copy number per cell. In iPSC, just one copy 
of the inducible construct will be recombined.  
This result allows to continue with the workflow as initially designed since expression of tdT as protein 
indicates the production of the RNA with tdT and the pre-miRNA. 
6.1.1.4 Analysis of miRNA processing to obtain mature mir4435 in Hek293 
The transfected cultures with and without induction were processed for total RNA extraction and 
retrotranscription of microRNA. The correct processing of the miRNA in Hek293 was evaluated by qPCR 
of the mature miR-4435. Unfortunately, the outcome of this experiment showed no amplification in 
any of the tested samples for miR-4435, but it was positive for the normalizer miRNA (RNU6). The lack 
of a positive control within this experiment does not allow to obtain a conclusive result: either the 
miRNA expression assay for miR-4435 failed or the miRNA is not being processed properly in Hek293 
from the transgenic construct. Time constrains did not permit to repeat this experiment. 
6.2 Replacement of tdT by BFP for iPSC functional characterization of the mir4435 
MiR-4435 overexpression effect at the molecualr and electrophysiological levels will be carried out in 
vitro in CM-iPSCs. For electrophysiological measurementes, optical mapping techniques will be used. 
Optical mappin uses fluorescente probes to measure calcium concentrations and voltage. Thes probes 
have emission spectra close to tdT. Therefore, the tdT has to be replaced by tagBFP (blue fluorescent 
protein). TagBFP will allow to follow miRNA expression in the cell culture, but will not overlap with the 
Rhod-2 spectrum of the calcium probe. 
6.2.1 Cloning of BFP to replace tdT reporter gene 
PCR amplification of tagBFP using V15 as templated, was succesfully achieved as reported in figure 
15A. tdT was excised out from V39 by digestion with AgeI and AscI (Figure 15B). The BFP fragment, 
obtained by PCR, was also digested with the same enzyme combination and purified before ligation. 
Ligation was performed with a 1:3 and 1:5 (vector:insert) molecular ratio. 
After bacterial transformation with the ligation product, only two colonies were grown that putatively 
contained the recombinant vector. However, none of them showed the expected restriction pattern 





Figure 15. Cloning of BFP into V39 to replace tdT reporter gene. A) PCR amplification of tagBFP (BFP). 
The band observed corresponds to the BFP amplicon at the expected molecular weight (699 pb).B) 
Enzymatic digestion of V39 to excise out tdT. The high molecular weight bad was purified. The lowest 
ban corresponds to the tdT at the expected molecular weight (1477 pb).C) Restriction digestion of two 












CVDs  are the most important cause of death in the world and one of the major triggers for CVD is 
aging, which is concomitantly increasing in the same direction. Due to the increasing prevalence of 
CVD, new effective therapies are needed. Targeting pathways dysregulated in CVD and with age as 
well as possible genetic background leading to disease might help to palliate what in the next few years 
could be considered as a non-infectious pandemic disease, age-related CVD.  
Dysregulation of miRNAs have been demonstrated to alter diverse signalling pathways being both the 
cause and the result of many pathological conditions, including in CVD. Thus, understanding the gene-
miRNA interactions that participate in such processes may be translated into putative therapies to 
prevent CVD or accelerated aging and its detrimental effects in the heart and vasculature. Also to be 
used as biomarkers. Biomarkers of accelerated aging, would be a huge advance, since it will allow early 
treatment (prevention) before the onset of CVDs. On top of that, understanding how miRNAs act and 
the targets they have could be decisive for an extraordinary change in how CVDs have been treated so 
far, allowing for personalization of the medicine. By performing analysis of the miRNA profiles in an 
individual, a specific drug to target the miRNAs that are dysregulated could be designed. 
miRNA therapeutics studies related to CVD are gaining more relevance since they have showed good 
results in preclinical studies [135]. However, animal models possess a homogeneous genetic 
background and they cannot mimic the long-term natural conditions (age, lifestyle, comorbidities) 
under which the disease is developed in humans, since disease models in animals are commonly 
abruptly induced either via genetic mutations or surgery. Therefore, despite the fact that animal 
models of CVD are essential to study its pathophysiological mechanisms as well as to test newly 
developed drugs before entering into clinical trials, their translational to human value remains limited. 
As it has been observed by Phase II and Phase III clinical trials failure rates are over 50% of drugs proved 
to be effective in preclinical models. Novel in vitro systems of human origin, like iPSC-CM, EHTs or 
myocardial slices, might be efficient tools to advance in miRNA therapies development with 
translational value [136]. In fact when EHT are mixed with fibroblast or endothelial cells, they have 
improved mimic adult phenotypes, since they show rod-shaped cardiomyocytes with well-organized 
sarcomere structures, systolic contraction, and inotropic responses to drug stimulation [136]. 
A major drawback for the successful development of miRNA therapeutics is effective delivery, naked 
charged RNAs tend to be cleared from the systemic circulation and on top of that, once they reach or 





Another issue that can occur, as it happens with the miR-25 TuD, is that the seed sequence of the 
antimiR molecule besides binding its original target (miR-25), also binds miR-92a. This is due to the fact 
that the miR-17-92 family presents the same seed sequence than miR-25. Taking into account that 
miR-92a is also upregulated in cardiac disease, in this case the off-target interaction could be 
beneficial. Another example of which off-target interactions could be beneficial is the case of the 
antagomir-122 (Miravirsen) that has successfully reach phase-II clinical trials offering long-term 
suppression for the treatment of patients with hepatitis C virus infection. Since miR-122, besides 
stabilizing RNA of the hepatitis C virus allowing no further replication, it is involved in the metabolism 
of hepatic cholesterol and fatty acids. Therefore, a reduction in miRNA-122 could have a double 
beneficial effect both inhibiting the virus replication and decreasing the cholesterol levels in plasma. 
In vivo studies both in mice and non-human primates would support this hypothesis, since miR-122 
inhibition resulted in decreased total cholesterol plasma levels[137]. 
However, if an antimiR interacted with a miRNA that tends to be downregulated in cardiac disease or 
aging, it would only increase the damaging effects caused by a severe dysregulation.  
Tissue and cell-specific delivery might play an important role in miRNA-based therapies, since the same 
miRNA can have different functions in different organs or within the same tissue. So, in order to avoid 
unspecific interactions, delivery should be improved. An example, it would be an antimiR against miR-
146a, because although its downregulation after heart failure seems to be beneficial, miR-146a 
function in vascular aging is still controverted [125], [126].  
Furthermore, immune adverse response due to the drug itself (it has been mostly reported in the case 
of miRNA mimics) or the vehicle that contains it are concerning. For instance, liposome linked toxicity, 
since it is one of the used carriers. Therefore, low immunogenic carriers that are capable of effectively 
reaching and entering through the lipidic bilayer should be developed to further success in future 
research. 
In the case of the miRNA mimics it is thought that because of its double stranded nature they easily 
induce the secretion of inflammatory cytokines and type I interferons (IFNs) when they bind to Toll-
like receptors (TLRs) [138], and that would be the main cause of the immune rejection of these 
therapies. Therefore, hiding them from these proteins or encapsulating them in low immunogenic 
recipients should diminish the adverse reaction and increase their therapeutic effects. 
Besides most miRNA therapeutics being still on the preclinical phase, and with only two miRNA based 
drugs in clinical trials (LNA-anti-miR 92a and antimir-132), miRNAs therapeutics remain promising 




before (immunogenicity and effective delivery), since miRNAs are key post-transcriptional controllers 
of gene expression. 
So far, only two miRNA therapies to treat CVD are on clinical phase of testing. Therapy repurposing of 
miRNA therapies in more advanced stages than CVDs’ ones, but with putative effect to treat them, 
could be another approach to accelerate miRNA-based treatment of CVD. Coupling of such 
therapeutics with highly specialized tissue delivery, like nanocarriers functionalized for specific 
recognition only in the cardiac tissue, such as RNA aptamers [139], or local delivery by inhaled 
nanoparticles[83], could allow to apply these therapies. 
The experimental work of my Master thesis continues previous research of the BSICoS group were 
putative interactions of BIO-AGEmiRNA (mir24-2 and mir4435) with target genes were demonstrated 
in vitro using luciferase reporter assays [15], [16] Here, tools to carry out further investigations of the 
functional effect of such interactions in vitro are developed and partly tested. Inducible expression 
vectors containing the BIO-AGEmiRNAs (mir24-2, miR-4435 and miR-3916) were attempted to 
develop. These vectors are suitable for RMCE in human iPSC [17]. The future goal is to regulate by 
inducible expression the BIO-AGEmiRNA in CM-iPSC to observe the molecular and functional effect at 
electrophysiological level using optical mapping techniques. Unfortunately, only vector containing 
miR-4435 (V39) was successfully created, since amplification of miR-3916 and miR 24-2 were not 
successful. 
The mir4435 inducible expression vector was tested in Hek293. Three different transfection conditions 
were designed in order to analyse miR4435 expression: Non-transfected cells and V39 transfected cells 
with or without induction. The tdT fluorescent protein was used to report for transgene expression. 
Natural fluorescence of Hek293 cells was set as background for microscopy analysis. Upon induction, 
clear tdT signal was observed, however the TetO promoter seems to have some leakage as non-
induced cells expressed the reporter protein (low red fluorescence). A more sensitive variant of this 
promoter such as the dox-controlled HIV-1 [140] could be considered in case substitution would be 
needed in in vitro or in vivo experiments. This will be extremely beneficial, because lower doses of 
doxycycline will prevent both promoter leakage and will have a lesser impact disturbing the 
microbiome of the animal model, which could lead to either disease or antibiotic resistance.  
qPCR of the transfected Hek293 was performed to analyse the correct maturation of miR-4435 in vitro. 
However, non-conclusive results were obtained and due time limitations this step could not be 
properly assessed. Still, according to published works [141], [142, p. 99], it is expected that the DNA 





Future work will be done so that miR24-2 and miR3916, that are being synthetically synthesized, will 
be cloned as well to create their inducible expression vectors compatible with optical mapping 
techniques. Furthermore, if miRNA analysis in iPSC validation of miRNA-target interaction resulted in 
measurable functional impact in human cardiomyocyte physiology, a direct relationship could be 
established between BIO-AGEmiRNA and cellular function. In this case, more complex in vivo studies 
might be considered in order to study their significance as possible targets for anti-aging therapeutics. 
8. CONCLUSIONS 
 miRNA therapies are avidly investigated in cardiovascular research since miRNA have been 
demonstrated to be involved in CVD and aging. 
 Two major challenges for miRNA therapies need to be overcome to fulfil their expected 
potential in CVD treatment: improved deliveries and reduced immunogenicity. 
 As of now, two miRNA-based therapeutics for CVD have reach clinical trials. 
 MiRNA therapy repurposing coupled with highly specialized tissue-directed drug delivery 
could be a significant approach to accelerate miRNA-based treatments in CVD. 
 An miRNA inducible expression vector compatible with rapid genome engineering by 
RMCE has been created. 
 This vector has been partially tested. It is expected to become a useful tool for proceeding 
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Table A1. Cloned regions  






Table A2. Primers for PCR amplification Blue: MluI, Red: AscI, Purple: PacI, Orange: AgeI, 
Green: EcoRV. 
Amplicon Oligonucleotide Sequence (5’3’) 
Tm 
(°C) 
 Tm used 






















































































Denaturation 98 10 s 
Anneling X 30 s 



















Denaturation 95 30 s 
Anneling X 30 s 






Hold 4 ∞ 
Reactive Final concentration 
Nuclease-Free Water  
5X HF Buffer  1X 
dNTPs 2 mM 200 μM 
Forward primer 10 μM 0.5 μM 
Reverse primer 10 μM 0.5 μM 
Phusion Taq DNA polymerase  0.02 U/μL 





Table A5. Colony PCR reactives 
 
 
Table A6. Restriction enzymes. 
 
Table A7. Oligonucleotide sequence employed for DNA sequencing. Blue: MluI, Red: AscI, 
Purple: PacI 
 
Reactive Final concentration 
Nuclease-Free Water  
5X Nzytaq II Reaction Buffer (NEB) 1X 
MgCl2 Solution, 25 mM 1,5  μM 
dNTPs 2 mM 200 μM 
Forward primer 10 μM 0.25 μM 
Reverse primer 10 μM 0.25 μM 
Nzytaq II DNA polymerase 0.02 U/μL 
Bacterial lysate 5 μL 
Restriction Enzyme Recognition Sequence Type Company Reference 
Nco I C'CATG,G ANZA 20 u/µl Thermo IVGN0214 
Age I A'CCGG,T ANZA 20 u/µl Thermo IVGN0074 
Mlu I A'CGCG,T ANZA 20 u/µl Thermo IVGN0286 
Asc I GG'C GCG,CC ANZA 20 u/µl Thermo IVGN0214 
Hind III A'AGCT,T STANDARD 10 u/µl Thermo ER0501 
Oligonucleotide Sequence (5’3’) 
Pre-miR-4435 (Forward) AAAACGCGTGGCGCGCCTCCTCCCCATTTCTGTACTG 
Pre-miR-4435 (Reverse) ATTACGCGTTTAATTAAGGAACTTCAGACTCATGCC 















P253 (Forward) hsa-miRNA-4435-5p  CCAGAGCTCACACAGAGGAA 
P133 (Universal primer) 
(Rverse) 
RNU6  and  hsa-miRNA-4435-5p  
GCATAGACCTGAATGGCGGTA 
P096 (Forward) RNU6  CGCAAGGATGACACGCAAAT 
